Latest Breaking News On - Robert langreth - Page 7 : comparemela.com

Aspartame is possibly carcinogenic, but safe at common usage levels: WHO studies

The FDA said it disagrees with IARC’s conclusion that these studies support classifying aspartame as a possible carcinogen to humans

British columbiaNew yorkUnited statesHugh johnstonJohn sicherArnold baskiesPaul pharoahDasha afanasievaFrancesco brancaRobert langrethDeena shankerKevin keaneLos angelesGarrett nelsonWorld health organizationCola co

Artificial sweetener aspartame is possibly carcinogenic, yet safe at common use levels, who says | Region

Concern about aspartame’s health risks was reawakened after one unit of the World Health Organization classified the artificial sweetener as a possible carcinogen and another agency cleared the substance for

United statesDasha afanasievaLos angelesPaul pharoahKevin keaneArnold baskiesFrancesco brancaRobert langrethKevin mcconwayDeena shankerHugh johnstonAmerican cancer societyWorld health organizationInternational agency for research on cancerAgriculture organization of the united nationsCola co

Artificial Sweetener Aspartame Is Possibly Carcinogenic, Yet Safe at Common Use Levels, WHO Says

Artificial Sweetener Aspartame Is Possibly Carcinogenic, Yet Safe at Common Use Levels, WHO Says
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.

United statesFrancesco brancaJohn sicherKevin keaneGarrett nelsonHugh johnstonArnold baskiesDasha afanasievaDeena shankerLos angelesRobert langrethPaul pharoahWorld health organizationInternational agency for research on cancerAmerican beverage associationDepartment of nutrition

Obesity Pills: Race to develop weight-loss pills has some drugmakers falling behind

Weight Loss Pills: Novo and Lilly's experimental obesity pills helped people lose about 15% of body weight, similar to weight-loss shots on the market already, according to findings presented

United statesMichael shahMila bankovskaiaDaniel druckerMatthew griffinNovo nordiskRichard dimarchiJohn murphyRobert langrethNovo wegovyIndiana universityGemma courtEli lilly coAmerican diabetes associationUniversity of torontoPfizer inc

Breakthrough in Alzheimer s research: the pros and cons of two new drugs

The emergence of two new drugs to treat Alzheimer's disease provides a rare burst of hope for the field of Alzheimer's research.

Robert langrethEli lillyLisa jarvisNadya swartUs national institute onAlzheimer disease internationalEuropean unionBiogen incEisai coEli lilly coDrug administrationNew drugsTreat alzheimerDisease international